-
Nov 14, 2024 | 
healio.com | Diana V Do |Alex Young |Anthony DeFino |Diana Do MD
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Jul 29, 2024 | 
healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the ASRS meeting, Diana V.
-
Nov 27, 2023 | 
healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Eamon Dreisbach
You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this Healio Video Perspective from the AAO meeting, Diana V.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. When encountering a patient with diabetic macular edema and diabetic retinopathy, I try to individualize the approach for each patient.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Diabetic macular edema is also a very challenging disease to treat because patients have to come back frequently for evaluations with their retina specialists and treatment.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Diabetic macular edema is treated with intravitreal anti-VEGF therapies such as aflibercept 2 mg, ranibizumab 0.3 mg or off-label bevacizumab. But more recently, the exciting developments include the FDA approval of faricimab, the first bispecific that’s being used to treat retinal vascular diseases.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Vision education is extremely important. We know that patients may have initial symptoms of blurry vision when they first have diabetic macular edema, and when patients experience these changes in their vision, it’s important for them to see their health care professional for evaluation.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Diabetic macular edema is still a very challenging disease to treat because it’s chronic and patients often have recurrence of their edema. With the more recently approved 8 mg of aflibercept and 6 mg of faricimab, physicians have more treatment options for their patients while decreasing the treatment burden of frequent office visits.
-
Oct 11, 2023 | 
healio.com | Diana Do MD
Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The recent FDA approval of faricimab, the first bispecific intravitreal agent that blocks both VEGF and angiopoietin-2 is an exciting development.
-
Aug 14, 2023 | 
healio.com | Diana V Do |Anthony DeFino |Diana Do MD |Christine Klimanskis
Source/Disclosures
Source:
Do DV. Aflibercept 8 mg for diabetic macular edema: 2-year results from the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Disclosures:
Do reports having financial disclosures for Boehringer Ingelheim, Genentech, Kodiak Sciences, Kriya and Regeneron.
You've successfully added to your alerts. You will receive an email when new content is published.
